ArticleTheranostics2022
Single-cell atlases link macrophages and CD8
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
13.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 57 citations in OpenAlex.
- Immune Phenotype in Urothelial Carcinoma: From Tumor Biology to Therapeutic Stratification.Cancers · 2026Review
- An integrative epigenomic and single-cell framework identifies a prognostic DNA methylation risk score and ZNF638 silencing in urothelial carcinoma.Journal of translational medicine · 2026Article
- Article
- Single-cell RNA sequencing in ovarian cancer: decoding the tumor microenvironment for personalized therapy.Journal of ovarian research · 2026Review
- Aberrant p53 fuels macrophage immunoregulatory polarization and refractory clinical outcome in urothelial carcinoma.Journal for immunotherapy of cancer · 2026Article
- The tumor-associated fibroblasts regulate urothelial carcinoma progression.Journal of molecular cell biology · 2026Article
- Medea: An omics AI agent for therapeutic discovery.bioRxiv : the preprint server for biology · 2026Article
- Article
- Attenuated crosstalk between urothelium and fibroblasts promotes ureteral stricture development.Frontiers in immunology · 2026Article
- Novel hypoxia-immune biomarkers predict response to neoadjuvant chemotherapy in patients with laryngo-hypopharyngeal cancer.European journal of medical research · 2025Article
- Single-cell sequencing in bladder cancer: new insights from tumor cell diversity to individualized treatment strategies.Cancer cell international · 2025Review
- Construction of a gene-metabolite-microbiome regulatory network reveals novel therapeutic targets in bladder cancer through multi-omics analysis.Annals of medicine · 2025Article
- IL-6Journal of translational medicine · 2025Article
- Deficient DNA mismatch repair and Nectin-4 expression in upper tract urothelial carcinoma (UTUC).Journal of cancer research and clinical oncology · 2025Article
- Single-cell sequencing technology in renal cancer: insights into tumor biology and clinical application.Biomarker research · 2025Review
- Article
- Sketching T cell atlases in the single-cell era: challenges and recommendations.Immunology and cell biology · 2025Review
- Article
- Sepsis-related immune signature C3 in endometrial carcinoma: implications for prognosis, tumor progression through bioinformatics and experimental validation.Molecular biology reports · 2025Article
- Acinar cells modulate the tumor microenvironment through the promotion of M1 macrophage polarization via macrophage endocytosis in pancreatic cancer.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 6 institutions in 3 countries.
Yuan LiangCAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation, Beijing 100101, China.
Yezhen TanCAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation, Beijing 100101, China.
Bao GuanDepartment of Urology, Peking University First Hospital, Beijing 100034, China.
Bin GuoCAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation, Beijing 100101, China.
Mancheng XiaDepartment of Urology, Peking University First Hospital, Beijing 100034, China.
Juan LiCAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation, Beijing 100101, China.
Yue ShiCAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation, Beijing 100101, China.
Zihui YuCAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation, Beijing 100101, China.
Qi ZhangCAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation, Beijing 100101, China.
Di LiuCore Facility for Protein Research, Institute of Biophysics, Chinese Academy of Science, Beijing 100101, China.
Xiaopeng YangCore Facility for Protein Research, Institute of Biophysics, Chinese Academy of Science, Beijing 100101, China.
Junfeng HaoCore Facility for Protein Research, Institute of Biophysics, Chinese Academy of Science, Beijing 100101, China.
Yanqing GongDepartment of Urology, Peking University First Hospital, Beijing 100034, China.
Muhammad ShakeelJamil-ur-Rahman Center for Genome Research, Dr. Panjwani Center for Molecular Medicine and Drug Research, ICCBS, University of Karachi, Karachi, Pakistan.
Liqun ZhouDepartment of Urology, Peking University First Hospital, Beijing 100034, China.
Weimin CiCAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation, Beijing 100101, China.
Xuesong LiDepartment of Urology, Peking University First Hospital, Beijing 100034, China.
Beijing Institute of Genomics · CNChinese Academy of Sciences · CNPeking University · CNPeking University First Hospital · CNUniversity of Chinese Academy of Sciences · CNUniversity of Karachi · PK
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Carcinoma, Transitional CellUrinary Bladder NeoplasmsCD8-Positive T-LymphocytesDisease ProgressionHumansImmune Checkpoint InhibitorsImmunologic FactorsImmunosuppressive AgentsImmunotherapyMacrophagesTumor MicroenvironmentImmune Checkpoint InhibitorsImmunologic FactorsImmunosuppressive AgentsImmunosuppressionImmunotherapySingle-cell RNA sequencingTumor microenvironmentUrothelial carcinoma
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.